Valuation dashboard for Damora Therapeutics, Inc. (GLTO) with P/E N/A, P/B 0.68, EV/EBITDA 1.90 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients.
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At the current price of $21.58, GLTO has negative trailing earnings (P/E not meaningful) and an ROE of -82.56%. Market capitalisation stands at $34M.
Balance sheet quality for GLTO: current ratio of 13.0. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 0.68 |
| EV / EBITDA | 1.90 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $176.42 |
| vs Current Price | +717.5% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| GLTO | Damora Therapeutics, Inc. | $34M | 0.68 | -82.6% | |
| RPRX | Royalty Pharma plc | $26.0B | 24.39 | 3.83 | |
| CORT | Corcept Therapeutics Incorporated | $12.1B | 207.35 | 16.10 | 8.4% |
| 0I3Q.L | Corcept Therapeutics Incorporated | $11.7B | 217.89 | 16.92 | 8.4% |
| LQDA | Liquidia Corporation | $6.1B | 42.09 | 30.09 | |
| KNSA | Kiniksa Pharmaceuticals International, plc | $5.8B | 70.23 | 8.91 | 13.7% |
| 0HF9.L | Amicus Therapeutics, Inc. | $5.3B | 19.37 | -12.0% | |
| PBH | Prestige Consumer Healthcare Inc. | $2.2B | 13.05 | 1.16 |
Price
| Price | $21.58 |
| Market Cap | $34M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -82.56% |
| Return on Invested Capital | -52.44% |
| Return on Assets | -48.35% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ACXP · ADIL · APRE · APVO · BCDA · INAB · KPRX
Explore sector: Healthcare · Medical - Pharmaceuticals
More sections of GLTO: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks